New data show treatment with etesevimab (JS016) and bamlanivimab together reduced risk of COVID-19 hospitalizations and death by 70 percent

    NEXT STORY
    Fishawack Health Acquires Both The Hive Health Group and StoneArch
    PREV STORY
    Crohn’s and Colitis Canada Celebrates the 10th Anniversary of the AbbVie IBD Scholarship Program
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2020 Financial Results

    author_avatar
    NASDAQ Market News

    Mesoblast Reports Financial Results and Corporate Highlights for First Half Ended December 31, 2019

    author_avatar
    NASDAQ Market News

    CytomX Therapeutics Announces Teleconference and Webcast to Provide Corporate Update

    SOUTH SAN FRANCISCO, Calif., March 19, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), ...

    author_avatar
    NASDAQ Market News